Latest news with #ImpediMed
News.com.au
30-04-2025
- Business
- News.com.au
Health Check: Impedimed says ‘nuts' to tariffs as it squirrels away components
By stockpiling components, the US-focused Impedimed is taking no chances with tariffs Cashed-up Amplia forges ahead with promising pancreatic cancer trial Some biotechs are headed to the well, while others are rolling in the green stuff The maker of Sozo lymphoedema measurement devices, ImpediMed (ASX:IPD) says it will spend $1.2 million to stockpile foreign componentry in the US. CEO Parmjot Bains today said the items would be bought at 'pre-tariff prices to further reduce the risk of disruption.' Earlier this month Impedimed said it expected 'no material impact' from tariffs, given its Sozos are made in the US from 'substantial US componentry'. But the squirrelling of parts – mainly electronic components ultimately sourced from Asian countries including Taiwan and Malaysia – highlights the measures US exposed device and drug makers are taking to avoid any collateral damage. The Trump administration has plonked a 32% tariff on Taiwan – the world's computer chip capital – although the impost is on pause and open for negotiation with the Great Dealmaker. Impedimed, meanwhile, has pledged to rev up its US sales. This is despite posting record March quarter revenue of $3.4 million, 31% higher year on year. The company sold 36 Sozo units, 22 in the US. "While there's a lot to like in the result … we still need to see a significant acceleration in US sales," Bains said. And sales teams take note: she expects improved US turnover for the rest of the calendar year. After burning $3.5 million during the quarter, Impedimed had a lush $27.8 million cash balance. This includes a US$10 million drawdown on a US$15 million loan facility. Hitherto assessed with a tape measure, lymphoedema is the swelling of limbs because of cancer treatment. Amplia advances pancreatic cancer trial Amplia (ASX:ATX) today said it had $10.9 million in its kitty after expending $2.7 million during the quarter. This makes management even more confident of completing its encouraging local pancreatic cancer trial. Dubbed Accent, the 55-patient phase IIa trial tests Amplia's narmafotinib (AMP-945) alongside the standard-of-care chemotherapy (gemcitabine). In an update on Monday, the company said of the 29 advanced pancreatic cancer patients assessed to date, 11 had a partial response. This means they had a tumour shrinkage of 30% or more, sustained for at last two months. This response rate of 38% compares with the historical average of 23% for chemo alone. The results also show the patients remained on the trial for a median 208 days, compared with 117 days for the chemo-alone group. 'That's probably the most important data, because we expect that will translate into progression-free survival (PFS) data and ultimately overall survival (OS).' says Amplia CEO Dr Chris Burns. Burns, by the way, co-invented the US-approved myelofibrosis drug Ojjaara. PFS is the length of time a patient lives with a disease without the disease getting worse. OS is the length of time from diagnosis or treatment until death, regardless of the cause of death. 'That's what you care about as a patient: how long am I able to take these drugs to stop the disease progressing," Burns says. The company expects a read-out on PFS data in the September quarter. Pancreatic cancer is one of the deadliest of all cancers, with an average nine months' life expectancy with the current chemotherapy. 'Commercially, while it is challenging you don't have to do a lot for it to be meaningful,' Burns says. Time to rattle the can … With today marking the cut-off for March quarter reports, lodgements are flooding in like Wivenhoe Dam after one of these one-in-100-year floods that happen every couple of years. While there's plenty of cheer, some biotechs clearly need cash if they are to remain viable. A developer of natural pesticides and insecticides, Bio-Gene Technology (ASX:BGT) had cash burn of $644,000 and no revenue, reducing its cash to $683,000. 'A capital raising is imminent and the company believes these activities will be successful in raising cash,' the company says. Bio-Gene also has US$3 million in grants across two US military programs, including a push to banish bed bugs (an itchy problem in those shared dorms). Opyl (ASX:OPL) late yesterday reported receipts of $2000 and burn of $262,000, taking its cash to a mere $64,000. The company also has $380,000 of drawn loans and $25,000 of loan headroom. Today, Opyl shares entered trading halt as the company was 'considering, planning and executing a capital raising'. Opyl is interesting, having developed an algorithmic tool to predict the outcome of clinical trials (and to run them optimally). The developer of blood and glucose tests and quality control assays for winemakers, Universal Biosensors (ASX:UBI) upped receipts by 28%, to $1.6 million. But the company's burn of $3.7 million reduced cash to $4.9 million. Universal is having capital raising discussions with 'various interested stakeholders' and the 'likelihood of success is high'. Device innovator Hydrix (ASX:HYD) has a lot of groundbreaking projects. But with its cash whittled down to $289,000, short-term survival is the key and management is taking action including chasing tardy debtors. … while others are rolling in cash Mesoblast (ASX:MSB) burnt through US$12.7 million but has a handy US$182 million in the bank as it commercialises its now US-approved treatment for paediatric graft-versus-host disease. Genetic Signatures (ASX:GSS) is also strongly positioned, with $37.4 million of cash, having burnt a modest $300,000 in the quarter. Genetic also posted $2.9 million of sales, up 71%. As with Mesoblast, the company is in the early stages of US commercialisation, for its recently approved gastrointestinal bug test Easyscreen. Percheron Therapeutics (ASX:PER) burnt $4.47 million during the quarter and ended up with $12.9 million of cash. The dosh is the residue of a capital raising to support Percheron's now-abandoned Duchenne muscular dystrophy program. Having survived a second board spill last week, management is scouring for an alternative asset to deploy the residual spendoolies. Orthocell (ASX:OCC) earlier reported a generous cash balance of $31.7 million. That's more than enough to support Orthocell's product commercialisation including the rollout of its Remplir nerve repair device in the US. But the stock spiked up to 13% this morning for a different reason: Canada – a.k.a. the 51 st state – has also approved Remplir.
Yahoo
07-02-2025
- Business
- Yahoo
ImpediMed Secures $15m Growth Capital Funding
New round will help fuel commercialization efforts in support of ImpediMed's platform technology for the detection and monitoring of lymphedema. CARLSBAD, Calif., Feb. 7, 2025 /PRNewswire/ -- ImpediMed, a leader in medical technologies to clinically monitor and manage fluid and body composition, today announced an agreement for a five-year $15 million growth capital facility with SWK Holdings (NASDAQ:SWKH), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies. Funds raised will provide ImpediMed with funding flexibility and will be used to support growth and commercialization activities. Armentum Partners acted as the Company's exclusive financial advisor on this transaction. With this new funding in place, ImpediMed's capital base is well equipped to support the continued execution of its commercial strategy. As a result, the company is better positioned than ever to achieve its long-term goals and create significant value for its shareholders. As a pioneer in the field of lymphedema detection and monitoring, ImpediMed offers the only FDA-cleared bioimpedance spectroscopy (BIS) technology for the clinical assessment of breast cancer-related lymphedema (BCRL) –– the SOZO® Digital Health Platform. ImpediMed's platform is broadly accepted and recognized for effective and accurate screening of lymphedema, with U.S. health payors now providing coverage for over 258 million covered lives. Lymphedema, a common consequence of cancer treatment, is challenging to detect before symptoms appear. ImpediMed's SOZO® Digital Health Platform uses BIS to identify fluid changes early, enabling intervention before lymphedema becomes a chronic condition. With growing adoption in clinical practice and increasing payor coverage, ImpediMed's innovative approach is transforming lymphedema management. In 2024, the National Accreditation Program for Breast Centers (NABPC) updated its accreditation standards to include lymphedema prevention programs utilizing BIS as an evidence-based guideline for managing lymphedema. The NAPBC is a quality program of the American College of Surgeons, and accredited programs must understand, implement, and demonstrate compliance with accreditation standards outlined in Optimal Resources for Breast Care. This recognition further validates BIS as a critical tool in lymphedema management and presents a significant opportunity for ImpediMed to expand its reach, driving broader adoption of the SOZO Digital Health Platform across breast cancer centers nationwide.1 "We are pleased with our agreement with SWK Holdings and the confidence they have shown in ImpediMed, as well as in the future of our SOZO Digital Health Platform," said Dr. Parmjot Bains, MD, CEO & Managing Director of ImpediMed. "SWK's proven approach of supporting innovative healthcare companies makes them an ideal partner for us as we pursue our commercial growth strategy over the next five years. We are confident with the business' direction, and this was reinforced throughout our due diligence process. In conjunction with our existing cash reserves, this facility gives us the time and funding flexibility required to execute on our business plan and fully capitalize on the BCRL opportunity." "We believe that the SOZO Digital Health Platform is revolutionizing how clinicians assess and manage fluid and body composition, ultimately improving patient outcomes," said JD Tamas, Director of Underwriting at SWK Holdings. "We are excited to provide this capital to support ImpediMed's continued mission to improve the lives of patients by pushing the boundaries of what's possible in fluid and tissue analysis." About SOZO Digital Health Platform SOZO, the world's most advanced, non-invasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphoedema, provides fluid status for patients living with heart or renal failure, and can be used to monitor and maintain overall health – all on a single device. About SWK Holdings SWK Holdings is a life science focused specialty finance company partnering with small- and mid-sized commercial-stage healthcare companies. SWK provides non-dilutive financing to fuel the development and commercialization of lifesaving and life-enhancing medical technologies and products. SWK's unique financing structures provide flexible financing solutions at an attractive cost of capital to create long-term value for all SWK stakeholders. SWK's solutions include structured debt, traditional royalty monetization, synthetic royalty transactions, and asset purchases typically ranging in size from $5.0 million to $25.0 million About Armentum Partners Armentum Partners is an investment bank dedicated to assisting healthcare and technology companies access non-dilutive capital. Since the beginning of 2023, Armentum has raised over $3.5 billion for its clients. About ImpediMed Founded in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximize patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally. In March 2024, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship continue to reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business. For more information, visit 1 Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the American College of Surgeons. Content does not reflect the views or interpretations of the American College of Surgeons. Media Contact:Jodi PerkinsAmendola Communications, on behalf of ImpediMedjperkins@ View original content to download multimedia: SOURCE ImpediMed Sign in to access your portfolio
Yahoo
05-02-2025
- Business
- Yahoo
ImpediMed (ASX:IPD) investors are sitting on a loss of 72% if they invested three years ago
As every investor would know, not every swing hits the sweet spot. But really big losses can really drag down an overall portfolio. So take a moment to sympathize with the long term shareholders of ImpediMed Limited (ASX:IPD), who have seen the share price tank a massive 72% over a three year period. That'd be enough to cause even the strongest minds some disquiet. And the ride hasn't got any smoother in recent times over the last year, with the price 39% lower in that time. Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns. Check out our latest analysis for ImpediMed Given that ImpediMed didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size. In the last three years, ImpediMed saw its revenue grow by 4.9% per year, compound. That's not a very high growth rate considering it doesn't make profits. But the share price crash at 20% per year does seem a bit harsh! While we're definitely wary of the stock, after that kind of performance, it could be an over-reaction. Before considering a purchase, take a look at the losses the company is racking up. The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image). We consider it positive that insiders have made significant purchases in the last year. Even so, future earnings will be far more important to whether current shareholders make money. So we recommend checking out this free report showing consensus forecasts Investors in ImpediMed had a tough year, with a total loss of 39%, against a market gain of about 14%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 9% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 1 warning sign we've spotted with ImpediMed . If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the radar). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
